While most studies on HHI resistance have focused on tumor‐intrinsic mechanisms, including canonical mutations in SMO, SUFU, or GLI2 that reactivate HH signaling, these alterations alone do not fully explain clinical variability in treatment response [23, 24, 25]. The gene discussed is GLI2; the disease is neoplasm.